0001493152-23-033815.txt : 20230927
0001493152-23-033815.hdr.sgml : 20230927
20230927060559
ACCESSION NUMBER: 0001493152-23-033815
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230926
FILED AS OF DATE: 20230927
DATE AS OF CHANGE: 20230927
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: van der Baan Bastiaan Jeroen
CENTRAL INDEX KEY: 0001938070
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39717
FILM NUMBER: 231281745
MAIL ADDRESS:
STREET 1: HOGEWEG 4-H
CITY: AMSTERDAM
STATE: P7
ZIP: 1098CB
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: LIXTE BIOTECHNOLOGY HOLDINGS, INC.
CENTRAL INDEX KEY: 0001335105
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 202903526
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 248 ROUTE 25A
STREET 2: NO. 2
CITY: EAST SETAUKET
STATE: NY
ZIP: 11733
BUSINESS PHONE: 310 203 2902
MAIL ADDRESS:
STREET 1: 248 ROUTE 25A
STREET 2: NO. 2
CITY: EAST SETAUKET
STATE: NY
ZIP: 11733
FORMER COMPANY:
FORMER CONFORMED NAME: SRKP 7 INC
DATE OF NAME CHANGE: 20050803
4
1
ownership.xml
X0508
4
2023-09-26
0
0001335105
LIXTE BIOTECHNOLOGY HOLDINGS, INC.
LIXT
0001938070
van der Baan Bastiaan Jeroen
HOGEWEG 4-H
AMSTERDAM
P7
P71098CB
NETHERLANDS
1
1
0
0
President and CEO
0
Options to Purchase Common Stock
1.95
2023-09-26
4
A
0
250000
0
A
2028-09-26
Common
250000
250000
D
Options to Purchase Common Stock
5.88
2023-06-30
4
A
0
10000
0
A
2023-06-30
2028-06-30
Common
10000
10000
D
Options to Purchase Common Stock
7.40
2022-06-17
4
A
0
25000
0
A
2022-06-17
2027-06-17
Common
25000
25000
D
In connection with the Employment Agreement dated as of September 26, 2023 between the Company and the reporting person, the reporting person was granted stock options to purchase an aggregate of 250,000 shares of common stock, vesting quarterly over a three-year period commencing on the last day of each calendar quarter commencing October 1, 2023 until fully vested.
NOTE: Effective June 2, 2023, the Issuer effected a 1-for-10 reverse split of its outstanding shares of common stock. Accordingly, the exercise price and the amount of underlying shares of common stock set forth above for all transactions entered into prior to that date have been adjusted to reflect the reverse stock split.
/s/ Bastiaan van der Baan
2023-09-27